Which medications are known to cause drug‑induced lichenoid dermatitis?

Medications Known to Cause Drug-Induced Lichenoid Dermatitis

Checkpoint inhibitors, tyrosine kinase inhibitors, beta-blockers, ACE inhibitors, antimalarials, thiazide diuretics, and TNF-alpha antagonists are the most commonly implicated medications in drug-induced lichenoid dermatitis, with checkpoint inhibitors now representing the leading cause in contemporary practice. 1

Most Frequently Implicated Drug Classes

Oncologic Agents (Most Common in Modern Practice)

• Checkpoint inhibitors are now the most frequently reported culprit drugs, accounting for 42.1% of all reported cases of lichenoid drug eruptions 1
• Tyrosine kinase inhibitors represent 12% of cases 1
• Anti-TNF-alpha monoclonal antibodies account for 4% of cases 1, 2

Cardiovascular Medications (Classic Culprits)

• Beta-blockers have sufficient evidence with five or more cases reported in at least three separate reports establishing probable causation 3
• ACE inhibitors (ramipril, enalapril, quinapril) are associated with lichenoid eruptions 4, 2, 3
• Thiazide diuretics (including hydrochlorothiazide, bumetanide, furosemide, indapamide) can trigger lichenoid eruptions 4
• Methyldopa has sufficient evidence for causation 3
• Calcium channel blockers (amlodipine, diltiazem, nifedipine) are implicated 4
• Angiotensin receptor blockers (candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan) are associated with lichenoid reactions 4

Other Established Culprits

• Antimalarial drugs (gold, antimalarials) are classic triggers 2, 3
• Penicillamine has sufficient evidence for causation 3
• Quinidine and quinine have established causative roles 3
• Spironolactone has been reported to cause lichenoid drug eruptions 5
• Oral hypoglycemic agents (sulfonylureas) are associated with oral lichenoid reactions 3, 6

Additional Medications with Reported Associations

• NSAIDs (ampiroxicam, celecoxib, diclofenac, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam) should be considered causative based on epidemiologic evidence 4, 3
• Statins (atorvastatin, pravastatin, simvastatin) are implicated 4
• Anti-arrhythmic drugs (amiodarone, dronedarone) are associated 4
• Antidepressants (citalopram, escitalopram, fluoxetine, paroxetine, sertraline) are reported triggers 4
• Antihistamines (cetirizine, loratadine) and corticosteroids (methylprednisolone) have rare case reports 7

Key Clinical Characteristics

Timing and Presentation

• The mean latency between drug initiation and eruption manifestation is 15.7 weeks (range: 0.1-208 weeks) 1
• After discontinuing the culprit drug, median time to resolution is 14.2 weeks (range: 0.71-416 weeks) 1
• Lesions typically present as symmetric, erythematous, violaceous papules reminiscent of lichen planus, often in UV-exposed areas 1, 2

Important Clinical Distinction

• Drug-induced lichenoid eruptions differ from idiopathic lichen planus primarily by their temporal relationship to drug initiation and resolution upon drug discontinuation 3
• The culprit drug requires discontinuation in only 26% of cases, which is low compared to other adverse drug reactions, likely due to favorable benefit/risk ratios in cancer therapy 1

Management Approach

Treatment Modalities

• 42.1% of patients are treated with topical corticosteroids 1
• 16.7% of patients require systemic glucocorticoids 1
• High-potency topical corticosteroids (clobetasol 0.05% or fluocinonide 0.05% gel) are first-line for oral lichenoid reactions 8, 9
• For refractory cases, systemic immunomodulators (methotrexate, azathioprine, cyclosporine) may be considered in consultation with oncology 4, 8

Critical Pitfall to Avoid

• Do not automatically discontinue oncologic agents (checkpoint inhibitors, TKIs) without weighing tumor response benefits against dermatologic toxicity, as most cases can be managed with topical therapy while continuing the cancer treatment 1, 10